Associated Papers
Pharmacokinetic recall study of Estonian Biobank participants with novel genetic variants in CYP2C19 and CYP2D6.
Krebs K et al.
Npj Genomic Medicine, 2026
Genetic variants of cytochrome P450 2C21 identified by screening 6344 dogs influenced oxidations of the probe drug omeprazole.
Uno Y et al.
Biochemical Pharmacology, 2025
Genetic and clinical factors associated with the metabolism of valproic acid in post-neurosurgery patients.
Cai X et al.
Progress in Neuro-psychopharmacology & Biological Psychiatry, 2025
Whole exome sequencing reveals an FCGBP variant associated with spontaneous intraabdominal hemorrhage in severe acute pancreatitis.
Tang QY et al.
Imetaomics, 2025
Impact of cyclosporine A-related single nucleotide polymorphisms on post-transplant outcomes in pediatric hematologic malignancy patients undergoing allogeneic hematopoietic stem cell transplantation.
Ji Q et al.
Frontiers in Immunology, 2025
In vitro assessment of the impact of 30 CYP2C19 variants on citalopram metabolism.
Wang P et al.
Peerj, 2025
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP2C19 and non-SSRI/non-TCA antidepressants.
Beunk L et al.
European Journal of Human Genetics : Ejhg, 2024
Impact of CYP2C19 Gene Variants on Long-Term Treatment with Atorvastatin in Patients with Acute Coronary Syndromes.
Čereškevičius D et al.
International Journal of Molecular Sciences, 2024
Clinical application of a real-time polymerase chain reaction test for CYP2C19 genotyping based on genotype distribution in a healthy Korean population.
Park K et al.
Laboratory Medicine, 2024
Frequencies of pharmacogenomic alleles across biogeographic groups in a large-scale biobank.
Li B et al.
American Journal of Human Genetics, 2023
Functional evaluation of CYP2C19 and CYP3A4 gene polymorphism on ibuprofen metabolism.
Yuan LJ et al.
Toxicology and Applied Pharmacology, 2023
The influence of temperature on the metabolic activity of CYP2C9, CYP2C19, and CYP3A4 genetic variants in vitro.
Kojima M et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2023
Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.
Chamboko CR et al.
International Journal of Molecular Sciences, 2023
Whole-exome sequencing identified recurrent and novel variants in benzene-induced leukemia.
Lin D et al.
Bmc Medical Genomics, 2023
Distribution of a novel CYP2C haplotype in Native American populations.
Fernandes VC et al.
Frontiers in Genetics, 2023
Targeted haplotyping in pharmacogenomics using Oxford Nanopore Technologies' adaptive sampling.
Deserranno K et al.
Frontiers in Pharmacology, 2023
Association of Inherited Genetic Factors With Drug-Induced Hepatic Damage Among Children With Acute Lymphoblastic Leukemia.
Yang W et al.
Jama Network Open, 2022
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.
Brouwer JMJL et al.
European Journal of Human Genetics : Ejhg, 2022
Effects of CYP2C19 variants on the metabolism of tapentadol in vitro.
Xu RA et al.
Iranian Journal of Basic Medical Sciences, 2022
Genetic Variant ABCC1 rs45511401 Is Associated with Increased Response to Statins in Patients with Familial Hypercholesterolemia.
Dagli-Hernandez C et al.
Pharmaceutics, 2022
CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis: A GeT-RM Collaborative Project.
Gaedigk A et al.
The Journal of Molecular Diagnostics : Jmd, 2022
Effects of 31 recombinant CYP2C19 variants on clomipramine metabolism in vitro.
Lan T et al.
Journal of Psychopharmacology (oxford, England), 2021
Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study.
van der Perk MEM et al.
Cancers, 2021
A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram.
Bråten LS et al.
Clinical Pharmacology and Therapeutics, 2021
Allele frequencies of single nucleotide polymorphisms of clinically important drug-metabolizing enzymes CYP2C9, CYP2C19, and CYP3A4 in a Thai population.
Sukprasong R et al.
Scientific Reports, 2021
Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics.
Morales-Rosado JA et al.
Cardiovascular Drugs and Therapy, 2021
Han Chinese specific cytochrome P450 polymorphisms and their impact on the metabolism of anti-hypertensive drugs with adrenoreceptor blocking properties.
Qian JC et al.
Expert Opinion on Drug Metabolism & Toxicology, 2021
SLCO1B1: Application and Limitations of Deep Mutational Scanning for Genomic Missense Variant Function.
Zhang L et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2021
PharmVar GeneFocus: CYP2C19.
Botton MR et al.
Clinical Pharmacology and Therapeutics, 2021
Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration in immunocompromised children.
Espinoza N et al.
Scientific Reports, 2019
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Site-Directed Mutagenesis of Cytochrome P450 2D6 and 2C19 Enzymes: Expression and Spectral Characterization of Naturally Occurring Allelic Variants.
Dong AN et al.
Applied Biochemistry and Biotechnology, 2018
Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population.
Hiratsuka M et al.
Drug Metabolism and Pharmacokinetics, 2018
Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
Novkovic M et al.
European Journal of Clinical Pharmacology, 2018
The effects of cytochrome P450 2C19 polymorphism on the metabolism of voriconazole in vitro.
Xu RA et al.
Infection and Drug Resistance, 2018
In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestane.
Peterson A et al.
Pharmacology Research & Perspectives, 2017
Effects of CYP2C19 variants on methadone metabolism in vitro.
Lan T et al.
Drug Testing and Analysis, 2017
Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening.
Ng D et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017
Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine.
Zaiou M et al.
Clinical Genetics, 2017
In Vitro Functional Characterisation of Cytochrome P450 (CYP) 2C19 Allelic Variants CYP2C19*23 and CYP2C19*24.
Lau PS et al.
Biochemical Genetics, 2017
Effects of CYP2C19 Variants on Fluoxetine Metabolism in vitro.
Fang P et al.
Pharmacology, 2017
Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors.
Deshpande N et al.
Meta Gene, 2016
Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content.
Shirasaka Y et al.
The Pharmacogenomics Journal, 2016